Search Result

Results for "

PDAC mice

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) c-Myc (1) Claudin (1) Drug Derivative (1) Early 2 Factor (E2F) (1) Fluorescent Dye (1) Interleukin Related (1) MDM-2/p53 (1) MMP (2) MyD88 (1) NF-κB (1) NOD-like Receptor (NLR) (1) Reactive Oxygen Species (ROS) (2) Sirtuin (1) Tau Protein (1) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Inflammation/Immunology (1) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101194

Tin protoporphyrin IX dichloride Maximum Cited Publications 20 Publications Verification Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX	Reactive Oxygen Species (ROS)	Cancer
Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model .

HY-160818

MC3138 2 Publications Verification	Sirtuin	Cancer
MC3138 is a selective SIRT5 activator. MC3138 has antitumor activity on human PDAC cells, with IC₅₀ values of 25.4-236.9 μM. MC3138 combined with Gemcitabine (HY-17026) significantly inhibits tumor growth in mice .

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

HY-P1676

cyclo(RLsKDK) 2 Publications Verification BK-1361	MMP	Cancer
cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer .

HY-P1676A

cyclo(RLsKDK) TFA 2 Publications Verification BK-1361 TFA	MMP	Cancer
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer .

HY-P11785

Cpe30 MT2	Claudin	Cancer
Cpe30 MT2 is a short peptide that binds tightly junction protein Claudin‑4 (CLDN4) with high affinity, with a K_d value of 1.97 nM. Cpe30 MT2 can be used for the synthesis of PET molecular imaging probes targeting pancreatic cancer .

HY-182241

JR4-187	c-Myc Early 2 Factor (E2F) TNF Receptor MDM-2/p53 Reactive Oxygen Species (ROS) Apoptosis	Cancer
JR4-187 is an orally active, copper-dependent anticancer agent. JR4-187 downregulates genes involved in oxidative phosphorylation, MYC targets and E2F targets in cancer cells, while upregulates genes involved in the TNF-α signaling pathway, p53 pathway and KRAS signaling pathway, and downregulates CTR1 protein . JR4-187 induces ROS production, apoptosis, copper-dependent cytotoxicity, and exhibits selective cytotoxicity against KRAS-mutant cancer cells. JR4-187 is well tolerated in mouse models of pancreatic cancer. JR4-187 can be used in research related to cancers such as pancreatic ductal adenocarcinoma, colon cancer and rectal cancer .

HY-183786

Anticancer agent 327	NF-κB Fluorescent Dye Drug Derivative Autophagy	Cancer
Anticancer agent 327, a fluorescent Andrographolide (HY-N0191) derivative, is an NF-κB p50 inhibitor. Anticancer agent 327 covalently binds to the p50 subunit of NF-κB. Anticancer agent 327 reduces levels of multiple oncogenic p53 proteins via the autophagy/lysosome pathway. Anticancer agent 327 can be used for the research of pancreatic ductal adenocarcinoma (Ex/Em = 488/515 nm)^[1].

Cat. No.	Product Name	Target	Research Area

HY-P1676

cyclo(RLsKDK) 2 Publications Verification BK-1361	MMP	Cancer
cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer .

HY-P1676A

cyclo(RLsKDK) TFA 2 Publications Verification BK-1361 TFA	MMP	Cancer
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer .

HY-P11785

Cpe30 MT2	Claudin	Cancer
Cpe30 MT2 is a short peptide that binds tightly junction protein Claudin‑4 (CLDN4) with high affinity, with a K_d value of 1.97 nM. Cpe30 MT2 can be used for the synthesis of PET molecular imaging probes targeting pancreatic cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.